Effects of endostatin and a new drug terpestacin against human neuroblastoma xenograft and cell lines.
New development in the vascular network is a significant process for the proliferation, as well as metastatic expand, of cancer cells that depends on a sufficient provider of oxygen and nutrients and the removal of waste products. New blood and lymphatic vessels form via step called angiogenesis and lymphangiogenesis. Angiogenesis is controlled by activator and inhibitor of some molecules. So many different proteins have been established as angiogenic activators and inhibitors. Grades of expression of angiogenic factors demonstrate the forcefulness of tumor cells. The advance of angiogenic inhibitors should help to decrease both mortality and morbidity from carcinomas. So many patients have received anti-angiogenic therapy to date. Nevertheless, their notional efficacy and anti-angiogenic treatments have not demonstrated to be useful in terms of long-term survival. There is a crucial need for a new close treatment plan combining anti-angiogenic agents with standard cyto-reductive treatments in the regulation of cancer.
Brain Korea 21 Project for Medical Science, Yonsei University College of Medicine, 134 Shinchon-dong, Seodaemun-gu, Seoul, 120-752, Korea.
Ki Cheong
KC
Park
Seung Hoon
SH
Choi
D020533:Angiogenesis Inhibitors / Q000494:pharmacology*; D000818:Animals; D001643:Bridged Bicyclo Compounds / Q000494:pharmacology; D002460:Cell Line; D043169:Endostatins / Q000494:pharmacology*; D064593:Heterografts / Q000187:drug effects*; D006801:Humans; D051379:Mice; D009447:Neuroblastoma / Q000188:drug therapy*; D014407:Tumor Cells, Cultured
D020533:Angiogenesis Inhibitors; D001643:Bridged Bicyclo Compounds; D043169:Endostatins; C080890:terpestacin